• Biohaven Advances Regulatory Efforts for BHV-0223, a Sublingual Form of ALS Therapy Rilutek
  • Ibudilast May Help Only Bulbar-Onset Patients, Early Analysis of Phase 2 Data Suggests
  • MT Pharma Presents Data on Edaravone for ALS at 2017 AAN Meeting
  • Common Gene Mutations May Link ALS and Schizophrenia, Study Reports
  • Stabilizing Motor Neuron Survival Protein Might Lead to New ALS Treatments, Harvard Researchers Find
  • Study of ALS Protein Behavior Brings Researchers Closer to Finding New Treatments
  • Project ALS Announces Don’t Talk-a-Thon Fundraising Event
  • New Research Brings Insights into Role of Mutated FUS Protein In ALS
  • HealthWell Foundation Launches Fund to Assist Medicare Patients Living with ALS
  • Suppressing Ataxin-2 Protein Extended Survival Rate in ALS Mice Study
  • Devlin Brothers’ 100-Day Journey Across US Will Raise Money for Project ALS
  • Israel’s BrainStorm Offers Encouraging Phase 2 Data on Stem-Cell Therapy NurOwn to Treat ALS